Northwestern Mutual Wealth Management Co. increased its holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 8.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,504 shares of the biopharmaceutical company’s stock after buying an additional 277 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Alexion Pharmaceuticals were worth $426,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. raised its position in Alexion Pharmaceuticals by 2,689.8% during the first quarter. BlackRock Inc. now owns 18,628,080 shares of the biopharmaceutical company’s stock valued at $2,258,467,000 after purchasing an additional 17,960,356 shares in the last quarter. Bank of Montreal Can raised its position in Alexion Pharmaceuticals by 628.8% during the second quarter. Bank of Montreal Can now owns 1,423,318 shares of the biopharmaceutical company’s stock valued at $173,174,000 after purchasing an additional 1,228,025 shares in the last quarter. Bessemer Group Inc. raised its position in Alexion Pharmaceuticals by 1,949,640.5% during the second quarter. Bessemer Group Inc. now owns 721,404 shares of the biopharmaceutical company’s stock valued at $87,772,000 after purchasing an additional 721,367 shares in the last quarter. State Street Corp raised its position in Alexion Pharmaceuticals by 6.8% during the first quarter. State Street Corp now owns 11,298,685 shares of the biopharmaceutical company’s stock valued at $1,369,846,000 after purchasing an additional 718,756 shares in the last quarter. Finally, Marshall Wace North America L.P. acquired a new position in Alexion Pharmaceuticals during the first quarter valued at approximately $65,219,000. Institutional investors own 94.26% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Northwestern Mutual Wealth Management Co. Has $426,000 Stake in Alexion Pharmaceuticals, Inc. (ALXN)” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/16/northwestern-mutual-wealth-management-co-has-426000-stake-in-alexion-pharmaceuticals-inc-alxn.html.

Several research analysts have commented on the stock. Royal Bank Of Canada assumed coverage on shares of Alexion Pharmaceuticals in a research report on Thursday. They set an “outperform” rating and a $161.00 price objective for the company. J P Morgan Chase & Co upgraded shares of Alexion Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $163.00 to $175.00 in a research report on Tuesday, September 5th. BMO Capital Markets restated an “outperform” rating and set a $173.00 price objective (up from $168.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday. Deutsche Bank AG restated a “buy” rating and set a $158.00 price objective (up from $153.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday. Finally, SunTrust Banks, Inc. restated a “buy” rating and set a $180.00 price objective (up from $170.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday. Five equities research analysts have rated the stock with a hold rating, twenty have issued a buy rating and three have given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $157.13.

In other Alexion Pharmaceuticals news, Director Ann M. Veneman sold 835 shares of the firm’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total value of $121,751.35. Following the sale, the director now owns 5,480 shares of the company’s stock, valued at approximately $799,038.80. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Ann M. Veneman sold 700 shares of the firm’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $137.74, for a total transaction of $96,418.00. Following the completion of the sale, the director now directly owns 6,315 shares in the company, valued at approximately $869,828.10. The disclosure for this sale can be found here. In the last three months, insiders sold 17,070 shares of company stock worth $2,416,869. Insiders own 4.35% of the company’s stock.

Shares of Alexion Pharmaceuticals, Inc. (ALXN) opened at 146.69 on Friday. Alexion Pharmaceuticals, Inc. has a 12 month low of $96.18 and a 12 month high of $149.34. The company has a market cap of $32.74 billion, a PE ratio of 63.61 and a beta of 1.40. The firm’s 50-day moving average is $138.83 and its 200-day moving average is $124.75.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.08 by $0.48. The business had revenue of $912.00 million for the quarter, compared to analyst estimates of $846.15 million. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The company’s revenue was up 21.1% on a year-over-year basis. During the same quarter last year, the firm earned $1.13 EPS. On average, equities research analysts predict that Alexion Pharmaceuticals, Inc. will post $5.62 earnings per share for the current year.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.